Effect of the HMG-CoA Reductase Inhibitor Rosuvastatin on Early Chronic Kidney Injury in Obese Zucker Rats Fed With an Atherogenic Diet

被引:30
|
作者
Reisin, Efrain [1 ]
Ebenezer, Philip J. [2 ]
Liao, Jie [1 ]
Lee, Benjamin S. [1 ]
Larroque, Michelle [1 ]
Hu, Xuejiao [3 ]
Aguilar, Erwin A. [1 ]
Morse, Stephen A. [1 ]
Francis, Joseph [2 ]
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Sect Nephrol & Hypertens, Dept Internal Med, New Orleans, LA 70112 USA
[2] Louisiana State Univ, Sch Vet Med, Baton Rouge, LA 70803 USA
[3] Tulane Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA
来源
关键词
Statin; Metabolic syndrome; Zucker rats; Renal function; Albuminuria; Glomerular injury; BLOOD-PRESSURE; INSULIN-RESISTANCE; METABOLIC SYNDROME; HYPERTENSION; ATORVASTATIN; PROGRESSION; MECHANISMS; DISEASE; STROKE; HYPERLIPIDEMIA;
D O I
10.1097/MAJ.0b013e3181b27195
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The obese Zucker rat (OZR) spontaneously develops hyperlipidemia, insulin resistance, and microalbuminuria. In this study, the initial metabolic, functional, and glomerular pathology in young OZR fed with an atherogenic diet resembles the characteristics of metabolic syndrome. Hyperlipidemia and other metabolic derangement cause early glomerular damage in OZR by 10 weeks of age, before overt diabetes is developed. Consequently, the effects of potential interventions should also be evaluated at the young age. In OZR fed with all atherogenic high-fat diet, low (5 mg/kg) and high (20 mg/kg) dosages of rosuvastatin started at 5 weeks and maintained for 10 weeks induced a significant improvement in metabolic abnormalities, blood pressure, and renal function, including microalbuminuria. The low dose of rosuvastatin significantly decreased mesangial expansion, and the high dose exerted a marked protective effect oil file development of both glomerular hypertrophy and mesangial expansion, The statin also attenuated the inflammatory expression in the kidney cortex.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 50 条
  • [1] Rosuvastatin - A new HMG-CoA reductase inhibitor for hypercholesterolemia
    Roach, AE
    Tsikouris, JP
    Haase, KK
    FORMULARY, 2002, 37 (04) : 179 - +
  • [2] Rosuvastatin: A high-potency HMG-CoA reductase inhibitor
    Lopez, Larry M.
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2005, 45 (04) : 503 - 513
  • [3] Pharmacological characteristics of rosuvastatin: A new HMG-CoA reductase inhibitor
    Bousquet, P
    Gayet, JL
    THERAPIE, 2003, 58 (02): : 113 - 121
  • [4] Rosuvastatin: A highly effective new HMG-CoA reductase inhibitor
    Olsson, AG
    McTaggart, F
    Raza, A
    CARDIOVASCULAR DRUG REVIEWS, 2002, 20 (04): : 303 - 328
  • [5] No effect of age or gender on the pharmacokinetics of rosuvastatin: A new HMG-CoA reductase inhibitor
    Martin, PD
    Dane, AL
    Nwose, OM
    Schneck, DW
    Warwick, MJ
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (10): : 1116 - 1121
  • [6] Effects of rosuvastatin, a new HMG-CoA reductase inhibitor, on neurovascular function in diabetic rats
    Cameron, NE
    Inkster, ME
    Nangle, MR
    Smith, GJ
    McTaggart, F
    Cotter, MA
    DIABETES, 2001, 50 : A184 - A184
  • [7] Clinical rationale for rosuvastatin, a potent new HMG-CoA reductase inhibitor
    Hanefeld, M
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2001, 55 (06) : 399 - 405
  • [8] Synthesis and characterization of Rosuvastatin calcium impurity A; a HMG-CoA reductase inhibitor
    Lee, Young Hee
    Viji, Mayavan
    Lee, Eunhwa
    Jo, Hyeju
    Yoo, Kyung
    Sim, Jaeuk
    Lee, Sunhwan
    Lee, Kiho
    Lee, Heesoon
    Jung, Jae-Kyung
    TETRAHEDRON LETTERS, 2017, 58 (26) : 2614 - 2617
  • [9] Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats
    Ikeda, Y
    Young, LH
    Lefer, AM
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2003, 41 (04) : 649 - 656
  • [10] HMG-CoA Reductase Inhibitors in Chronic Kidney Disease
    A. Olyaei
    J. L. Steffl
    J. MacLaughlan
    M. Trabolsi
    S. P. Quadri
    I. Abbasi
    E. Lerma
    American Journal of Cardiovascular Drugs, 2013, 13 : 385 - 398